Product Code: 978-1-68038-509-0
Inhalation Anesthesia Market Growth & Trends:
The global inhalation anesthesia market size is expected to reach USD 2.22 billion by 2030, registering a CAGR of 6.65% from 2025 to 2030, according to a new report by Grand View Research, Inc. Inhalation anesthetics offer shorter induction period and recovery time along with better efficacy and lesser adverse effects as compared to other alternatives, thus providing better anesthetic effect during surgical procedures. They also provide excellent control over the duration of anesthesia in the patient. Thus, inhalation anesthesia is being preferred over intravenous anesthesia due to these advantages.
Drugs administered through inhalation anesthesia have a quick onset of action even at low dose as compared to intravenous anesthesia. Using inhalation route for administration helps avoid excessive dosage and keeps the patient's autonomic functions intact. As these drugs are eliminated via lungs, they have lower chances of accumulation in the body. Hence, they result in lower risk of hepatotoxicity. In addition, drugs administered through inhalation route have limited tolerance and addiction level as compared to other alternatives routes.
With the launch of innovative respiratory products such as AnaConDa (Anaesthetic Conserving Device), administration of inhalation general anesthetic agents such as sevoflurane, isoflurane, & other agents have become easier. Inhalation anesthesia is considered to be the best alternative for patients who are on ventilation for more than 24 hours as it becomes easy to monitor the patient's health.
Major concern associated with anesthetic gas is that only 5% account for patient use and the rest 95% is released in the atmosphere, which leads to greenhouse effect of these gases. The comparative analysis of sevoflurane, isoflurane, and desflurane based on atmospheric time span and global atmospheric concentrations indicates that desflurane poses a high potential threat for environment.
Inhalation Anesthesia Market Report Highlights:
- The sevoflurane segment dominated the market with the largest market share and is expected to grow at a significant CAGR of 7.47% over the forecast period.
- In terms of application, the maintenance segment dominated the market with the largest share in 2024 and is the fastest-growing segment and is expected to grow at a CAGR of 6.73% over the forecast period.
- The hospital segment dominated the market in 2024 with a share of 68.52% due to various factors such as technological advancements, increasing surgical procedures, and a strong emphasis on patient safety and recovery.
- The North America inhalation anesthesia market dominated the global market and accounted for 52.77% of revenue share in 2024, largely driven by an increasing number of surgical procedures, advancements in technology, and a rising elderly population.
- The Asia Pacific inhalation anesthesia market is expected to grow at the fastest CAGR over the forecast period, driven by demographic changes, particularly the aging population and increased life expectancy, leading to a higher incidence of chronic diseases that necessitate surgical interventions.
Table of Contents
Chapter 1 Methodology and Scope
- 1.1 Market Segmentation and Scope
- 1.2 Regional Scope
- 1.2.1 Segment Definitions
- 1.2.1.1 Drug Segment
- 1.2.1.2 Application Segment
- 1.2.1.3 Application Segment
- 1.2.1.4 End Use Segment
- 1.3 Estimates and Forecast Timeline
- 1.4 Objectives
- 1.4.1 Objective - 1
- 1.4.2 Objective - 2
- 1.4.3 Objective - 3
- 1.5 Research Methodology
- 1.6 Information Procurement
- 1.6.1 Purchased Database
- 1.6.2 GVR's Internal Database
- 1.6.3 Secondary Sources
- 1.6.4 Primary Research
- 1.7 Information Or Data Analysis
- 1.7.1 Data Analysis Models
- 1.8 Market Formulation & Validation
- 1.9 Model Details
- 1.9.1 Commodity Flow Analysis
- 1.10 Research Assumptions
- 1.11 List of Secondary Sources
Chapter 2 Executive Summary
- 2.1 Market Snapshot
- 2.2 Drug and Application Segment Snapshot
- 2.3 End Use Segment Snapshot
- 2.4 Competitive Landscape Snapshot
Chapter 3 Inhalation Anesthesia Market Variables, Trends, and Scope
- 3.1 Market Lineage Outlook
- 3.1.1 Parent Market Outlook
- 3.1.2 Related/Ancillary Market Outlook
- 3.2 Market Dynamics
- 3.2.1 Market Driver Analysis
- 3.2.1.1 Rising Surgical Procedures Globally
- 3.2.1.2 Technological Advancements in Anesthesia Delivery Systems
- 3.2.1.3 Growing Geriatric Population and Prevalence of Chronic Diseases
- 3.2.2 Market Restraint Analysis
- 3.2.2.1 Environmental Concerns Regarding Anesthetic Gases
- 3.2.2.2 Adverse Effects Associated With Anesthesia
- 3.3 Business Environment Analysis
- 3.3.1 Swot Analysis; By Factor (Political & Legal, Economic, Social, Environmental, And Technological)
- 3.3.2 Porter's Five Forces Analysis
Chapter 4 Inhalation Anesthesia Market - Segment Analysis, by Drug, 2018 - 2030 (USD Million)
- 4.1 Inhalation Anesthesia Market: Drug Movement Analysis
- 4.2 Inhalation Anesthesia Market Estimates & Forecast, by Drug (USD Million)
- 4.2.1 Sevoflurane
- 4.2.2 Cdesflurane
- 4.2.3 Isoflurane
- 4.2.4 Others
Chapter 5 Inhalation Anesthesia Market - Segment Analysis, by Application, 2018 - 2030 (USD Million)
- 5.1 Inhalation Anesthesia Market: Application Movement Analysis
- 5.2 Inhalation Anesthesia Market Estimates & Forecast, by Application (USD Million)
- 5.2.1 Induction
- 5.2.2 Maintenance
Chapter 6 Inhalation Anesthesia Market - Segment Analysis, by End Use, 2018 - 2030 (USD Million)
- 6.1 Inhalation Anesthesia Market: End-Use Movement Analysis
- 6.2 Inhalation Anesthesia Market Estimates & Forecast, by End Use (USD Million)
- 6.2.1 Ghospitals
- 6.2.2 Ambulatory Surgical Centers
- 6.2.2 Others
Chapter 7 Inhalation Anesthesia Market - Segment Analysis, by Region, 2018 - 2030 (USD Million)
- 7.1 Inhalation Anesthesia Market: Regional Outlook
- 7.2 North America
- 7.2.1 North America Inhalation Anesthesia Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 7.2.2 U.S.
- 7.2.2.1 Key Country Dynamics
- 7.2.2.2 U.S. Inhalation Anesthesia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.2.2.3 Competitive Scenario
- 7.2.2.4 Regulatory Framework
- 7.2.3 Canada
- 7.2.3.1 Key Country Dynamics
- 7.2.3.2 Canada Inhalation Anesthesia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.2.3.3 Competitive Scenario
- 7.2.3.4 Regulatory Framework
- 7.3 Europe
- 7.3.1 Europe Inhalation Anesthesia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.2 UK
- 7.3.2.1 Key Country Dynamics
- 7.3.2.2 UK Inhalation Anesthesia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.2.3 Competitive Scenario
- 7.3.2.4 Regulatory Framework
- 7.3.3 Germany
- 7.3.3.1 Key Country Dynamics
- 7.3.3.2 Germany Inhalation Anesthesia Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 7.3.3.3 Competitive Scenario
- 7.3.3.4 Regulatory Framework
- 7.3.4 France
- 7.3.4.1 Key Country Dynamics
- 7.3.4.2 France Inhalation Anesthesia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.4.3 Competitive Scenario
- 7.3.4.4 Regulatory Framework
- 7.3.5 Spain
- 7.3.5.1 Key Country Dynamics
- 7.3.5.2 Spain Inhalation Anesthesia Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 7.3.5.3 Competitive Scenario
- 7.3.5.4 Regulatory Framework
- 7.3.6 Italy
- 7.3.6.1 Key Country Dynamics
- 7.3.6.2 Italy Inhalation Anesthesia Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 7.3.6.3 Competitive Scenario
- 7.3.6.4 Regulatory Framework
- 7.3.7 Denmark
- 7.3.7.1 Key Country Dynamics
- 7.3.7.2 Denmark Inhalation Anesthesia Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 7.3.7.3 Competitive Scenario
- 7.3.7.4 Regulatory Framework
- 7.3.8 Sweden
- 7.3.8.1 Key Country Dynamics
- 7.3.8.2 Sweden Inhalation Anesthesia Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 7.3.8.3 Competitive Scenario
- 7.3.8.4 Regulatory Framework
- 7.3.9 Norway
- 7.3.9.1 Key Country Dynamics
- 7.3.9.2 Norway Inhalation Anesthesia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.9.3 Competitive Scenario
- 7.3.9.4 Regulatory Framework
- 7.3.10 Rest Of Europe Inhalation Anesthesia Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 7.4 Asia Pacific
- 7.4.1 Asia Pacific Inhalation Anesthesia Market Estimated And Forecasts, 2018 - 2030 (USD Million)
- 7.4.2 Japan
- 7.4.2.1 Key Country Dynamics
- 7.4.2.2 Japan Inhalation Anesthesia Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 7.4.2.3 Competitive Scenario
- 7.4.2.4 Regulatory Framework
- 7.4.3 China
- 7.4.3.1 Key Country Dynamics
- 7.4.3.2 China Inhalation Anesthesia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.3.3 Competitive Scenario
- 7.4.3.4 Regulatory Framework
- 7.4.4 India
- 7.4.4.1 Key Country Dynamics
- 7.4.4.2 India Inhalation Anesthesia Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 7.4.4.3 Competitive Scenario
- 7.4.4.4 Regulatory Framework
- 7.4.5 Australia
- 7.4.5.1 Key Country Dynamics
- 7.4.5.2 Australia Inhalation Anesthesia Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 7.4.5.3 Competitive Scenario
- 7.4.5.4 Regulatory Framework
- 7.4.6 Thailand
- 7.4.6.1 Key Country Dynamics
- 7.4.6.2 Thailand Inhalation Anesthesia Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 7.4.6.3 Competitive Scenario
- 7.4.6.4 Regulatory Framework
- 7.4.7 South Korea
- 7.4.7.1 Key Country Dynamics
- 7.4.7.2 South Korea Inhalation Anesthesia Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 7.4.7.3 Competitive Scenario
- 7.4.7.4 Regulatory Framework
- 7.4.8 Rest Of Asia Pacific Inhalation Anesthesia Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 7.5 Latin America
- 7.5.1 Latin America Inhalation Anesthesia Market Estimated And Forecasts, 2018 - 2030 (USD Million)
- 7.5.2 Brazil
- 7.5.2.1 Key Country Dynamics
- 7.5.2.2 Brazil Inhalation Anesthesia Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 7.5.2.3 Competitive Scenario
- 7.5.2.4 Regulatory Framework
- 7.5.3 Mexico
- 7.5.3.1 Key Country Dynamics
- 7.5.3.2 Mexico Inhalation Anesthesia Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 7.5.3.3 Competitive Scenario
- 7.5.3.4 Regulatory Framework
- 7.5.4 Argentina
- 7.5.4.1 Key Country Dynamics
- 7.5.4.2 Argentina Inhalation Anesthesia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.4.3 Competitive Scenario
- 7.5.4.4 Regulatory Framework
- 7.5.5 Rest Of Latin America Inhalation Anesthesia Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 7.6 Middle East And Africa
- 7.6.1 Middle East And Africa Inhalation Anesthesia Market Estimated And Forecasts, 2018 - 2030 (USD Million)
- 7.6.2 South Africa
- 7.6.2.1 Key Country Dynamics
- 7.6.2.2 South Africa Inhalation Anesthesia Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 7.6.2.3 Competitive Scenario
- 7.6.2.4 Regulatory Framework
- 7.6.3 Saudi Arabia
- 7.6.3.1 Key Country Dynamics
- 7.6.3.2 Saudi Arabia Inhalation Anesthesia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.3.3 Competitive Scenario
- 7.6.3.4 Regulatory Framework
- 7.6.4 UAE
- 7.6.4.1 Key Country Dynamics
- 7.6.4.2 UAE Inhalation Anesthesia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.4.3 Competitive Scenario
- 7.6.4.4 Regulatory Framework
- 7.6.5 Kuwait
- 7.6.5.1 Key Country Dynamics
- 7.6.5.2 Kuwait Inhalation Anesthesia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.5.3 Competitive Scenario
- 7.6.5.4 Regulatory Framework
- 7.6.6 Rest of MEA Inhalation Anesthesia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 8. Competitive Landscape
- 8.1. Company Categorization
- 8.2. Strategy Mapping
- 8.2.1. New Product Launch
- 8.2.2. Partnerships
- 8.2.3. Acquisition
- 8.2.4. Collaboration
- 8.2.5. Funding
- 8.3. Key Company Market Share Analysis, 2024
- 8.4. Company Heat Map Analysis
- 8.5. Company Profiles
- 8.5.1. HALOCARBON PRODUCTS CORPORATION
- 8.5.1.1. Company Overview
- 8.5.1.2. Financial Performance
- 8.5.1.3. Product Benchmarking
- 8.5.1.4. Strategic Initiatives
- 8.5.2. BAXTER
- 8.5.2.1. Company Overview
- 8.5.2.2. Financial Performance
- 8.5.2.3. Product Benchmarking
- 8.5.2.4. Strategic Initiatives
- 8.5.3. ABBVIE INC
- 8.5.3.1. Company Overview
- 8.5.3.2. Financial Performance
- 8.5.3.3. Product Benchmarking
- 8.5.3.4. Strategic Initiatives
- 8.5.4. LUNAN PHARMACEUTICAL GROUP
- 8.5.4.1. Company Overview
- 8.5.4.2. Financial Performance
- 8.5.4.3. Product Benchmarking
- 8.5.4.4. Strategic Initiatives
- 8.5.5. PIRAMAL ENTERPRISES LTD
- 8.5.5.1. Company Overview
- 8.5.5.2. Financial Performance
- 8.5.5.3. Product Benchmarking
- 8.5.5.4. Strategic Initiatives
- 8.5.6. SANDOZ INTERNATIONAL GMBH
- 8.5.6.1. Company Overview
- 8.5.6.2. Financial Performance
- 8.5.6.3. Product Benchmarking
- 8.5.6.4. Strategic Initiatives
- 8.5.7. FRESENIUS KABI AG
- 8.5.7.1. Company Overview
- 8.5.7.2. Financial Performance
- 8.5.7.3. Product Benchmarking
- 8.5.7.4. Strategic Initiatives
Chapter 9 Conclusion